22 February 2021
Visiongain has published a new report on Organ Transplant Rejection Medications Market Report 2021-2031: Forecasts By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitors, Antibodies, Steroids, and Others), By Transplant Type (Kidney Transplant, Bone Marrow Transplant, Liver Transplant, Heart Transplant, Lung Transplant, and Other Transplants), By End User (Hospitals, Organ Transplant Centers, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Organ Transplant Rejection Medications market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global organ transplant rejection medications market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Organ Transplant Rejection Medications Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Organ Transplant Rejection Medications market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Growing Organ Transplantation around the World
The number of organ transplantation has increased very significantly over time and with the increasing therapeutic advancements it is expected to continuously rise over the forecast period. The increase in the organ transplantation is surging a huge demand for the organ transplant rejection medications to reduce the chances of organ transplant failure. Due to which growing organ transplantation around the world is working as a driver for the organ transplant rejection medications market.
Increasing Geriatric Population around the World
An increasing number of geriatric populations are being referred for and an increase in accessibility for organ transplantation. The rapid increase in organ transplant is being registered due to increase in the organ failure in the elder patients cases and the number of organ failure is increasing with rapid increase in geriatric population around the world from the last few decades. For instance: According to the United Nations, Department of Economic and Social Affairs, the Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Increasing organ failure in the elder patients is increasing the demand of organ transplant and is also increasing the demand for organ transplant rejection medications around the world. Due to which increasing geriatric population around the world is working as a driver for the organ transplant rejection medications market.
Increasing focus on Healthcare Infrastructure
Governments focus on healthcare infrastructure including healthcare facilities, organ banks for which the governments are taking necessary steps to establish cutting edge healthcare facilities. Increasing focus on healthcare infrastructure is expected to increase public spending and reliability on the healthcare system, which is expected to increase organ transplantation in the forecasted period and new opportunities for the organ transplant rejection medications market.
Increasing Therapeutic Advancements in Organ Transplant Rejection Medications
Organ failure has remained one of the most restraining factors for organ transplant. Various organ failure cases are leading researchers and manufactures for new researches and new patent applications for organ transplant rejection medications to reduce chances of organ failure and increase chance of new organ acceptance in the patient body. Currently, various of the manufacturers are engaged in research and development activities for organ transplant rejection medications which is expected to increase availability of most effective medications in the market and to create new growth opportunities for the market.
Top companies (Novartis AG, F. Hoffmann-La Roche Ltd., Astellas Pharma, Inc., and Pfizer, Inc.) constitute more than XX% share of the global Organ Transplant Rejection Medications market. Other companies profiled in the report include: AbbVie, Inc., Allergan plc., Bristol-Myers Squibb Company (BMS), Sanofi, Mylan Laboratories, Inc., and GlaxoSmithKline plc) others Some of the key developments are listed below:
● In 2020, Sandoz International GmbH has launched Dailiport which is a once-daily generic tacrolimus capsules. Dailiport/Conferoport is developed for usage for liver and kidney transplant. The launch will help the company widen revenue generation from a market focused product portfolio.
● In 2020, Lupin has launched generic Mycophenolic which is an acid delayed-release tablet. Mycophenolic is developed for prevention of organ rejection in kidney transplants. New Product launch will help the company to increase its market share in the organ transplant rejection medications market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market